Junshi Biological: VV116 new drug marketing application was accepted
Read Time:22 Second
Ltd. received the “Notice of Acceptance” approved by the State Drug Administration for the oral nucleoside anti-novel coronavirus (SARSCoV-2) drug deuterated rimivir hydrobromide tablets ( “VV116”) for the treatment of novel coronavirus infection was accepted as a new drug marketing application. There is uncertainty whether this new drug marketing application will be approved due to the long development cycle and many approval steps of drugs, which are susceptible to some uncertainties.
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %
0
0
Average Rating